Literature DB >> 8129799

Treatment of lupus interstitial lung disease with intravenous cyclophosphamide.

A R Eiser1, H M Shanies.   

Abstract

Intravenous pulse cyclophosphamide (IPC) was used to treat lupus interstitial lung disease in 2 patients. Vital capacity increased by 67-110% of baseline values with IPC treatment. Total lung capacity and diffusing capacity also improved. Dyspnea and other manifestations of lupus improved dramatically. This is the first report documenting the efficacy of the early use of IPC for acute and chronic interstitial lung disease associated with lupus.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8129799     DOI: 10.1002/art.1780370318

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  4 in total

Review 1.  Recognition and management of systemic lupus erythematosus.

Authors:  J O Schroeder; H H Euler
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

Review 2.  New therapies for systemic lupus erythematosus.

Authors:  F Goldblatt; D A Isenberg
Journal:  Clin Exp Immunol       Date:  2005-05       Impact factor: 4.330

3.  Fertility, ovarian failure, and pregnancy outcome in SLE patients treated with intravenous cyclophosphamide in Saudi Arabia.

Authors:  Abdurhman Saud Alarfaj; Najma Khalil
Journal:  Clin Rheumatol       Date:  2014-06-04       Impact factor: 2.980

Review 4.  Lupus and the Lungs: The Assessment and Management of Pulmonary Manifestations of Systemic Lupus Erythematosus.

Authors:  Raj Amarnani; Su-Ann Yeoh; Emma K Denneny; Chris Wincup
Journal:  Front Med (Lausanne)       Date:  2021-01-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.